| 臺大學術典藏 |
2021-09-09T07:52:48Z |
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: An open-label, randomized clinical trial
|
CHIH-CHIEH YU; Lai W.-T.; Shih K.-C.; Lin T.-H.; Lu C.-H.; Lai H.-J.; Hanson M.E.; Hwang J.-J. |
| 臺大學術典藏 |
2022-09-19T08:13:51Z |
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial
|
CHIH-CHIEH YU; Lai, Wen-Ter; Shih, Kuang-Chung; Lin, Tsung-Hsien; Lu, Chieh-Hua; Lai, Hung-Jen; Hanson, Mary E; HWANG, JUEY-JEN |
| 臺大學術典藏 |
2022-09-20T06:49:29Z |
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: An open-label, randomized clinical trial
|
Yu C.-C.; Lai W.-T.; Shih K.-C.; Lin T.-H.; Lu C.-H.; Lai H.-J.; Hanson M.E.; HWANG, JUEY-JEN |
| 淡江大學 |
2023-01-05 |
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study
|
Mau, Lih-wen |
| 臺大學術典藏 |
2021-02-05T06:29:19Z |
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Wen-Chien Chou;Yeh S.-P.;Hsiao L.-T.;Lin S.-F.;Chen Y.-C.;Chen T.-Y.;Laille E.;Galettis A.;Dong Q.;Songer S.;Beach C.L.; WEN-CHIEN CHOU; Yeh S.-P.; Hsiao L.-T.; Lin S.-F.; Chen Y.-C.; Chen T.-Y.; Laille E.; Galettis A.; Dong Q.; Songer S.; Beach C.L. |
| 國立成功大學 |
2017 |
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Chou, W.-C.;Yeh, S.-P.;Hsiao, L.-T.;Lin, S.-F.;Chen, Y.-C.;Chen, T.-Y.;Laille, E.;Galettis, A.;Dong, Q.;Songer, Songer S.;Beach, C.L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 國立臺灣大學 |
2012 |
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
|
Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chiun; Lee, Kuan-Der; Hsiao, Chi-Huang; Lu, Yen-Shen; Huang, Chien-Chung; Shen, Yin-Chun; Hsu, Chih-Hung; Cheng, Ann-Lii; 盧彥伸; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2021-08-11T03:46:47Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-06-10T06:11:09Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-09-30T03:22:25Z |
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
|
Aboud M.; Gartland M.; Smith K.; Girard P.-M.; Kahl L.P.; Blair E.A.; Angelis K.; Wynne B.; Vandermeulen K.; Underwood M.; Castelli F.; Brinson C.; Llibre J.M.; CHIEN-CHING HUNG |
| 國立成功大學 |
2019 |
Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy
|
Tsai, J.-J.;Ikeda, A.;Hong, S.B.;Likasitwattanakul, S.;Dash, A. |
| 國立臺灣大學 |
2003 |
Efficacy, Safety, and Tolerability of Pramipexole in Untreated and Levodopa-Treated Patients with Parkinson's Disease
|
楊智超; YANG, CHIH-CHAO |
| 臺大學術典藏 |
2018-09-10T04:25:48Z |
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease
|
Wong, K.S.;Lu, C.-S.;Shan, D.-E.;Yang, C.-C.;Tsoi, T.H.;Mok, V.; Chih-Chao Yang |
| 臺大學術典藏 |
2021-01-28T01:06:23Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
Cheng A.-L.;Cornelio G.;Shen L.;Price T.;Yang T.-S.;Chung I.J.;Dai G.-H.;Lin J.-K.;Sharma A.;Kun-Huei Yeh;Ma B.;Zaatar A.;Guan Z.;Masood N.;Srimuninnimit V.;Yau T.;Gibbs P.;Wang X.;Doval D.C.;Oh S.-T.;Shim B.Y.;Gorospe C.;Wang H.-M.;Sirachainan E.;Hill A.;Suh K.W.;Beier F.;Chatterjee S.;Lim R.; Cheng A.-L.; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; KUN-HUEI YEH; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 大葉大學 |
2014-11-30 |
Efficiencies of Chitosan Nanoparticles and Crab Shell Particles in Europium Uptake from Aqueous Solutions through Biosorption: Synthesis and Characterization
|
Cadogan, Elon Ishmael;Lee, Ching-Hwa;Popuri, Srinivasa R.;Lin, Hang-Yi |
| 國立成功大學 |
2011-08-01 |
Efficiencies of two-stage systems with fuzzy data
|
Kao, Chiang |
| 中國科技大學 |
2014-11-13 |
Efficiencies vs. importance- performance analysis for the leading smartphone brands of Apple, Samsung and HTC
|
安寶儀 |
| 南亞技術學院 |
2011-11 |
Efficiency analyses of ethanol-fueled solid oxide fuel cell power system
|
Hong, Wen-Tang;Yen, Tzu-Hsiang;Chung, Tsang-Dong;Huang, Cheng-Nan;Chen, Bao-Dong |
| 南亞技術學院 |
2008-06 |
Efficiency analyses of solid oxide fuel cell power plant systems
|
Chung, Tsang-Dong;Hong, Wen-Tang;Chyou, Yau-Pin;Yu, Dong-Di;Lin, Kin-Fu;Lee, Chien-Hsiung |
